



TABLE OF CONTENTS

- [A Call for Collaboration on World AIDS Day – message from FIND CEO](#)
- [WHO endorses first international standard for *P. falciparum* antigens](#)
- [Xpert Ultra TB test: Results of FIND's major multicentre evaluation are released](#)
- [FIND's malaria RDT interactive guide updated with Round 7 results](#)
- [Signing of Moscow Declaration to END TB](#)
- [Viral hepatitis diagnostics: The past, present and future](#)
- [New target product profile for a test that predicts progression of TB](#)
- [MSF, WHO & FIND seek expert feedback](#)
- [The malERA Refresh Consultative Panel on Basic Science and Enabling Technologies](#)
- [FIND at upcoming events](#)
- [Partner News & Resources](#)
- [Scientific articles by FIND staff & SAC](#)

A Call for Collaboration on World AIDS Day – message from FIND CEO

In honor of World AIDS Day, we at FIND join the voices around the globe that applaud the huge progress that has been made over the last decade, and call on the community to continue the vital work that will one day end this disease.

Thanks to that progress, HIV is no longer the world's leading infectious disease killer. The annual number of new cases has been falling since 2015. More than 20 million people are on antiretroviral therapy – a near threefold increase since 2010. [More...](#)



[Short video in honor of World AIDS Day 2017](#)

WHO endorses first international standard for *P. falciparum* antigens


• Jobs at FIND

TECHNICAL GUIDANCE

WHO World Malaria Report 2017



Global Tuberculosis Report



Stop TB Partnership & TAG report




Tuberculosis Research Funding Trends 2005-2016



The ability to evaluate RDT performance reliably and accurately using an internationally recognized reference standard is critical. FIND partnered with the National Institute for Biological Standards and Control to create the first World Health Organization International Standard (IS) for Plasmodium falciparum antigens. The IS was validated by an international collaborative study in 13 laboratories across 11 different countries. [More...](#)

Xpert Ultra TB test: Results of FIND's major multicentre evaluation are released



Results of an evaluation of the performance of Xpert® MTB/RIF Ultra (Ultra) are now available in the *Lancet ID*. Ultra is a second-generation, molecular tuberculosis test that has shown increased sensitivity over its predecessor. The assessment of Ultra's performance was conducted in 2016 in a multi-centre study at ten sites in eight low- and middle-income countries, coordinated by FIND, and conducted by FIND and the NIAID-sponsored Tuberculosis Clinical Diagnostics Research Consortium. [More...](#)

FIND's malaria RDT interactive guide updated with Round 7 results

Malaria RDT product testing: interactive guide

This interactive guide is designed to help select malaria RDTs with the specific performance characteristics required by national malaria control programmes, based on the results of the WHO/FIND malaria RDT product testing programme, Rounds 1-7.

HOME PAGE | [FAQ](#) | [CONTACT US](#)

Target species: All species | Test format: Any | Test type: All

Min. panel detection score* for P. falciparum (%): 75 | Max. strip position rate: 10 | %

Max. panel detection score** for P. vivax (%): 5 | Max. panel test rate: 3 | %

Blood volume: | Buffer drops: | Reading time: | Protocol group: | Read ability:

*Panel detection score and sensitivity in the field

Choose the parameters to display by clicking on the buttons below:

[Panel detection score & sensitivity](#) [Max. panel test rate](#) [Max. strip position rate](#) [False positive rates](#) [Max. test rate](#) [Mean results \(95% 200 parameters\)](#) [Mean results \(95% 200 parameters\)](#) [Mean results \(95% 200 parameters\)](#) [Mean results \(95% 200 parameters\)](#)

Table View | Chart View (select products to compare by clicking on any comparative view - 10 products)

Product	Manufacturer	Catalogue No.	200 parameters, P. falciparum sensitivity**	200 parameters, P. vivax sensitivity**	200 or 1000 parameters, P. falciparum sensitivity**	200 or 1000 parameters, P. vivax sensitivity**
ABON™ Plus Malaria PFAr Rapid Test Device (Whole Blood)	ABON Diagnostics (Singapore) Co., Ltd.	MA-102	80.7	5.9	100.0	87.1
ABON™ Malaria™ Rapid Malaria Antigen Detection Test	Abu Chemicals Private Limited	MS001217	80.0	N/A	100.0	N/A
ADONEX™ Diagnostic™ Rapid Malaria Antigen Test	Philo Products, Inc.	PTM001-002	80.0	N/A	99.2	N/A

The market for malaria rapid diagnostic tests (RDTs) consists of millions of RDTs sold annually, with more than 60 manufacturers and over 200 available products, many with a wide range of characteristics, prices and...quality! For procurers to be able to select the right product that meets minimum quality standards, and at the same time fits the needs of end-users and the constraints in areas where malaria is

prevalent, FIND provides an interactive guide allowing easy search using key criteria related to product performance, robustness, and test characteristics. The interactive guide has recently been updated with the Round 7 results of the last product testing. Since January 2017, over 5000 requests from 106 different countries have been registered, demonstrating that the guide successfully meets its purpose. [More...](#)

Signing of Moscow Declaration to END TB




Russian President Vladimir Putin has called on world leaders to “step up scientific tuberculosis research and develop effective diagnostic tools, vaccines and medicines, including those aimed at treating resistant forms of tuberculosis.” Speaking at the first WHO Global Ministerial Conference, *Ending tuberculosis in the SDG era: a multisectoral response*, President Putin emphasized the need for urgency and a collaborative approach to tackle TB. [More...](#)

Viral hepatitis diagnostics: The past, present and future



FIND co-authored six papers in a series published by BioMed Central (BMC) titled *Testing for chronic hepatitis B and C – a global perspective*. This supplement, funded by the World Health Organization (WHO), coincided with the 2017 World Hepatitis Summit in Brazil that took place early November. It includes essential articles relating to the WHO 2017 Guidelines on hepatitis B (HBV) and hepatitis C (HCV) testing, critical information on HBV and HCV diagnostics and recommendations for the global health community to combat these diseases. [More...](#)

New target product profile for a test that predicts progression of TB



The **End TB Strategy**, introduced by the World Health Organization and adopted by the World Health Assembly, aims to reduce TB-related deaths by 95% and new TB infections by 90% by 2035. Approximately one quarter to one third of the world's population is currently infected with the *M. tuberculosis* bacteria and the risk of developing an active form of the disease among infected individuals is between 5 and 15 percent. [More...](#)

MSF, WHO & FIND seek expert feedback

MSF, in partnership with WHO and FIND, has led the development of a target product profile (TPP) for a multiplex multi-analyte diagnostic platform technology. Essentially, a test capable of detecting a wide array of different disease markers using a single patient sample. The three organizations now seek public comments on the draft. [More...](#)

The malERA Refresh Consultative Panel on Basic Science and Enabling Technologies



In collaboration with the malaria community, MESA (Malaria Eradication Scientific Alliance) has led a consultative process to update the malaria eradication research agenda (malERA), bringing together more than 180 scientists, malaria programme managers and policy makers from around the world, including our very own Head of Malaria, Iveth González. malERA Refresh has now been published in PLOS Medicine. Congratulations to everyone involved! [View articles here.](#)

FIND at upcoming events

SAVE THE DATE: SAMRC and FIND invite you to join us at a regional stakeholders' summit titled – **AMR+Africa+Diagnostics: How can we work together to stem the tide of antimicrobial resistance?** – to be held in Cape Town, South Africa on 30 January 2018.

Partner News & Resources

Global Fund [Appoints Peter Sands as Executive Director](#).

Stop TB Partnership: [November newsletter](#)

WHO: [World AIDS Day 2017: Everybody counts](#)

WHO: [November Bulletin](#)

Scientific articles by FIND staff & SAC

Dorman SE, Schumacher SG, Alland D, Nabeta P, Armstrong DT, King B, Hall SL, Chakravorty S, Cirillo DM, Tukvadze N, Bablishvili N, Stevens W, Scott L, Rodrigues C, Kazi MI, Joloba M, Nakiyingi L, Nicol MP, Ghebrekristos Y, Anyango I, Murithi W, Dietze R, Peres RL, Skrahina A, Auchynka V, Chopra KK, Hanif M, Liu X, Yuan X, Boehme CC, Ellner JJ, Denkinger CM. **Xpert MTB/RIF for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study.** *Lancet Infect Dis*, Nov 2017. [View article](#)

Morrison CS, Homan R, Mack N, Seepolmuang P, Averill M, Taylor J, Osborn J, Dailey P, Parkin N, Ongarello S, Mastro TD. **Assays for estimating HIV incidence: updated global market assessment and estimated economic value.** *J Int AIDS Soc*, Nov 2017. [View article](#)

Naidoo P, Theron G, Rangaka MX, Chihota VN, Vaughan L, Brey ZO, Pillay Y. **The South African tuberculosis care cascade: Estimated losses and methodological challenges.** *J Infect Dis*, Nov 2017. [View article](#)

Matovu E, Kitibwa A, Picado A, Biéler S, Bessell PR, Ndung'u JM. **Serological tests for gambiense human African trypanosomiasis detect antibodies in cattle.** *Parasites & Vectors*, Nov 2017. [View article](#)

Ivanova Reipold E, Trianni A, Krakower D, Ongarello S, Roberts T, Easterbrook P, Denkinger CM. **Values, preferences and current hepatitis B and C testing practices in low- and middle-income countries: results of a survey of end users and implementers.** *BMC Infect Dis*, Nov 2017. [View article](#)

Ivanova Reipold E, Easterbrook P, Trianni A, Paneer N, Krakower D, Ongarello S, Roberts T, Miller V, Denkinger CM. **Optimising diagnosis of viraemic hepatitis C infection: the development of a target product profile.** *BMC Infect Dis*, Nov 2017. [View article](#)

Lange B, Cohn J, Roberts T, Camp J, Chauffour J, Gummedi N, Ishizaki A, Nagarathnam A, Tuailon E, van de Perre P, Pichler C, Easterbrook P, Denkinger CM. **Diagnostic accuracy of serological diagnosis of hepatitis C and B using dried blood spot samples**

(DBS): two systematic reviews and meta-analyses. *BMC Infect Dis*, Nov 2017. [View article](#)

Peeling RW, Boeras DI, Marinucci F, Easterbrook P. **The future of viral hepatitis testing: innovations in testing technologies and approaches.** *BMC Infect Dis*, Nov 2017. [View article](#)

Ishizaki A, Bouscaillou J, Luhmann N, Liu S, Chua R, Walsh N, Hess S, Ivanova E, Roberts T, Easterbrook P. **Survey of programmatic experiences and challenges in delivery of hepatitis B and C testing in low- and middle-income countries.** *BMC Infect Dis*, Nov 2017. [View article](#)

Lange B, Roberts T, Cohn J, Greenman J, Camp J, Ishizaki A, Messac L, Tuailon E, van de Perre P, Pichler C, Denkinge CM, Easterbrook P. **Diagnostic accuracy of detection and quantification of HBV-DNA and HCV-RNA using dried blood spot (DBS) samples – a systematic review and meta-analysis.** *BMC Infect Dis*, Nov 2017. [View article](#)

Jobs at FIND

Project Manager – HCV Programme, Kuala Lumpur, Malaysia:
Application deadline: 15 December 2017

Access Officer – Access Team, Kenya. Application deadline: 5 December 2017

You're receiving this email as a member of the FIND mailing list.

[Edit your subscription](#) | [Unsubscribe](#)

FIND
Campus Biotech
Chemin des Mines 9
1202 Geneva
www.finddx.org